Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
Passerini M, Schiavini M, Magni CF, Landonio S, Niero F, Passerini S, Croci AL, Bolis M, Scalzi V, Gubertini G, Ricci ED, Galli M, Rizzardini G. Passerini M, et al. Among authors: niero f. Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1208-1215. doi: 10.1097/MEG.0000000000001239. Eur J Gastroenterol Hepatol. 2018. PMID: 30138160
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.
Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, Baldin GM, Soria A, Riccardi N, Niero FP, Celesia BM, Barbarini G, Rusconi S, Rizzardini G. Capetti AF, et al. Among authors: niero fp. HIV Clin Trials. 2018 Dec;19(6):242-248. doi: 10.1080/15284336.2018.1550290. HIV Clin Trials. 2018. PMID: 30890064 Clinical Trial.
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.
Skowron G, Spritzler JG, Weidler J, Robbins GK, Johnson VA, Chan ES, Asmuth DM, Gandhi RT, Lie Y, Bates M, Pollard RB; NIH/NIAID ACTG 384 Protocol Team and Monogram Biosciences. Skowron G, et al. J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):250-8. doi: 10.1097/QAI.0b013e3181938faf. J Acquir Immune Defic Syndr. 2009. PMID: 19194319 Free PMC article. Clinical Trial.
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data.
Capetti AF, Cossu MV, Orofino G, Sterrantino G, Cenderello G, De Socio GV, Cattelan AM, Soria A, Rusconi S, Riccardi N, Baldin GM, Niero FP, Barbarini G, Rizzardini G. Capetti AF, et al. Among authors: niero fp. BMC Infect Dis. 2017 Sep 30;17(1):658. doi: 10.1186/s12879-017-2755-4. BMC Infect Dis. 2017. PMID: 28964268 Free PMC article.
29 results